Quick Answer
ARS Pharmaceuticals, Inc. reported Total Assets of $327.65 million for the year ending 2025.
- ARS Pharmaceuticals, Inc. showed a decrease of -6.7% in Total Assets from 2024 to 2025.
- This data is from ARS Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 9, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2021: $382.20 million | Q2 2021: $366.98 million | Q3 2021: $352.56 million | Q1 2022: $312.47 million | Q2 2022: $294.00 million | Q3 2022: $271.06 million | Q1 2023: $271.19 million | Q2 2023: $258.75 million | Q3 2023: $248.56 million | Q1 2024: $227.58 million | Q2 2024: $221.97 million | Q3 2024: $217.60 million | Q1 2025: $327.32 million | Q2 2025: $313.47 million | Q3 2025: $372.80 million.
- Over the full 6 years of available data (2020 to 2025), ARS Pharmaceuticals, Inc.'s Total Assets has declined by 17.0%.
- Historical annual values: Fiscal year 2025: $327.65 million | Fiscal year 2024: $351.15 million | Fiscal year 2023: $233.19 million | Fiscal year 2022: $281.44 million | Fiscal year 2021: $61.45 million | Fiscal year 2020: $394.80 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: